Activation of human granulocytes by intravenous immunoglobulin preparations is mediated by FcγRII and FcγRIII receptors

E. Nemes, Farkas Teichman, Dirk Roos, L. Máródi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Previous studies from our laboratory have shown that i.v, Ig (IVIG) exposure triggers superoxide anion (O2 -) generation by and increases bactericidal capacity of human blood granulocytes. However, the molecular interactions between IVIG and granulocytes have not been evaluated before. The objective of this study was to investigate the role of FcγRII and FcγRIII receptors in the immunomodulatory effects of IVIG concentrates on granulocytes. We found that four different IVIG preparations (concentration range, 1-10 mg/mL) shared the ability to stimulate O2 - release in vitro by granulocytes in a dose-dependent manner. Dimers fractionated from IVIG were significantly more potent in inducing activity of the respiratory burst than were monomers, MAb (concentration range, 0.1-10 μg/mL) specific for FcγRII and FcγRIII receptors inhibited the IVIG-induced O2 - release, with a more profound inhibitory effect observed with anti-FcγRIII. These findings suggest the involvement of Fcγ receptors in triggering O2 - release by granulocytes exposed to IVIG. We also report that IVIG added to granulocyte suspensions elicited a rapid and vigorous increase in the concentration of cytosolic free calcium, a finding suggesting direct activation and not priming of granulocytes by IVIG through FcγRII and FcγRIII receptors. The in vitro effects described here might occur in patients treated with IVIG and may, in part, be responsible for inflammatory reactions evoked by infused Ig concentrates as well as the immunomodulatory effect of Ig in patients with autoimmune and inflammatory diseases.

Original languageEnglish
Pages (from-to)357-361
Number of pages5
JournalPediatric Research
Volume47
Issue number3
Publication statusPublished - Mar 2000

Fingerprint

Intravenous Immunoglobulins
Granulocytes
Respiratory Burst
Fc Receptors
Superoxides
Autoimmune Diseases
Suspensions
Calcium

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Activation of human granulocytes by intravenous immunoglobulin preparations is mediated by FcγRII and FcγRIII receptors. / Nemes, E.; Teichman, Farkas; Roos, Dirk; Máródi, L.

In: Pediatric Research, Vol. 47, No. 3, 03.2000, p. 357-361.

Research output: Contribution to journalArticle

@article{5dfcddc4d3b549a9be6d289f66797dcb,
title = "Activation of human granulocytes by intravenous immunoglobulin preparations is mediated by FcγRII and FcγRIII receptors",
abstract = "Previous studies from our laboratory have shown that i.v, Ig (IVIG) exposure triggers superoxide anion (O2 -) generation by and increases bactericidal capacity of human blood granulocytes. However, the molecular interactions between IVIG and granulocytes have not been evaluated before. The objective of this study was to investigate the role of FcγRII and FcγRIII receptors in the immunomodulatory effects of IVIG concentrates on granulocytes. We found that four different IVIG preparations (concentration range, 1-10 mg/mL) shared the ability to stimulate O2 - release in vitro by granulocytes in a dose-dependent manner. Dimers fractionated from IVIG were significantly more potent in inducing activity of the respiratory burst than were monomers, MAb (concentration range, 0.1-10 μg/mL) specific for FcγRII and FcγRIII receptors inhibited the IVIG-induced O2 - release, with a more profound inhibitory effect observed with anti-FcγRIII. These findings suggest the involvement of Fcγ receptors in triggering O2 - release by granulocytes exposed to IVIG. We also report that IVIG added to granulocyte suspensions elicited a rapid and vigorous increase in the concentration of cytosolic free calcium, a finding suggesting direct activation and not priming of granulocytes by IVIG through FcγRII and FcγRIII receptors. The in vitro effects described here might occur in patients treated with IVIG and may, in part, be responsible for inflammatory reactions evoked by infused Ig concentrates as well as the immunomodulatory effect of Ig in patients with autoimmune and inflammatory diseases.",
author = "E. Nemes and Farkas Teichman and Dirk Roos and L. M{\'a}r{\'o}di",
year = "2000",
month = "3",
language = "English",
volume = "47",
pages = "357--361",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Activation of human granulocytes by intravenous immunoglobulin preparations is mediated by FcγRII and FcγRIII receptors

AU - Nemes, E.

AU - Teichman, Farkas

AU - Roos, Dirk

AU - Máródi, L.

PY - 2000/3

Y1 - 2000/3

N2 - Previous studies from our laboratory have shown that i.v, Ig (IVIG) exposure triggers superoxide anion (O2 -) generation by and increases bactericidal capacity of human blood granulocytes. However, the molecular interactions between IVIG and granulocytes have not been evaluated before. The objective of this study was to investigate the role of FcγRII and FcγRIII receptors in the immunomodulatory effects of IVIG concentrates on granulocytes. We found that four different IVIG preparations (concentration range, 1-10 mg/mL) shared the ability to stimulate O2 - release in vitro by granulocytes in a dose-dependent manner. Dimers fractionated from IVIG were significantly more potent in inducing activity of the respiratory burst than were monomers, MAb (concentration range, 0.1-10 μg/mL) specific for FcγRII and FcγRIII receptors inhibited the IVIG-induced O2 - release, with a more profound inhibitory effect observed with anti-FcγRIII. These findings suggest the involvement of Fcγ receptors in triggering O2 - release by granulocytes exposed to IVIG. We also report that IVIG added to granulocyte suspensions elicited a rapid and vigorous increase in the concentration of cytosolic free calcium, a finding suggesting direct activation and not priming of granulocytes by IVIG through FcγRII and FcγRIII receptors. The in vitro effects described here might occur in patients treated with IVIG and may, in part, be responsible for inflammatory reactions evoked by infused Ig concentrates as well as the immunomodulatory effect of Ig in patients with autoimmune and inflammatory diseases.

AB - Previous studies from our laboratory have shown that i.v, Ig (IVIG) exposure triggers superoxide anion (O2 -) generation by and increases bactericidal capacity of human blood granulocytes. However, the molecular interactions between IVIG and granulocytes have not been evaluated before. The objective of this study was to investigate the role of FcγRII and FcγRIII receptors in the immunomodulatory effects of IVIG concentrates on granulocytes. We found that four different IVIG preparations (concentration range, 1-10 mg/mL) shared the ability to stimulate O2 - release in vitro by granulocytes in a dose-dependent manner. Dimers fractionated from IVIG were significantly more potent in inducing activity of the respiratory burst than were monomers, MAb (concentration range, 0.1-10 μg/mL) specific for FcγRII and FcγRIII receptors inhibited the IVIG-induced O2 - release, with a more profound inhibitory effect observed with anti-FcγRIII. These findings suggest the involvement of Fcγ receptors in triggering O2 - release by granulocytes exposed to IVIG. We also report that IVIG added to granulocyte suspensions elicited a rapid and vigorous increase in the concentration of cytosolic free calcium, a finding suggesting direct activation and not priming of granulocytes by IVIG through FcγRII and FcγRIII receptors. The in vitro effects described here might occur in patients treated with IVIG and may, in part, be responsible for inflammatory reactions evoked by infused Ig concentrates as well as the immunomodulatory effect of Ig in patients with autoimmune and inflammatory diseases.

UR - http://www.scopus.com/inward/record.url?scp=0034000731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034000731&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 357

EP - 361

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 3

ER -